ClinConnect ClinConnect Logo
Search / Trial NCT05362929

Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color

Launched by ALBERT EINSTEIN COLLEGE OF MEDICINE · May 4, 2022

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Skin Of Color Fitzpatrick Skin Type Iii Fitzpatrick Skin Type Iv Fitzpatrick Skin Type V Acne Scarring Sciton

ClinConnect Summary

This clinical trial is exploring how effective and safe a special type of laser treatment is for reducing acne scars in individuals with skin of color. The laser being tested is a hybrid of two types—non-ablative (which means it doesn't remove the top layer of skin) and ablative (which does remove some skin). Researchers want to see how well this treatment works for people experiencing mixed types of acne scars and associated skin discoloration.

To join this study, participants need to be at least 18 years old and have been diagnosed with acne scars within the last six months. They should be in good health and not have smoked in the past year. It's important that they are willing to follow the study guidelines and not undergo other treatments for their scars during the trial. If eligible, participants can expect to receive the laser treatment and will need to attend follow-up appointments to monitor their progress. This study is currently looking for volunteers, so if you or someone you know fits the criteria and is interested, it may be a valuable opportunity to explore.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for acne scarring
  • Subject must voluntarily sign and date an IRB approved informed consent form
  • Subjects with diagnosis of acne scarring recorded over the past 6 months
  • Able to read, understand and voluntarily provide written informed consent.
  • Subject is determined to be healthy, non-smoker
  • Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements.
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.
  • Exclusion Criteria:
  • Subjects does not have the capacity to consent to the study
  • subject underwent any acne scar treatments in the past 6 months prior to enrollment in the study
  • Subject has active papulopustular or cystic acne within the past 6 months.
  • Any history of keloidal scarring.
  • Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months.
  • History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months.
  • * History or current use of the following prescription medications:
  • Immunosuppressive medications/biologics, 6 months prior to and during the study
  • Accutane or other systemic retinoids within the past twelve months
  • Smoking or vaping in the past 12 months.
  • History of photosensitivity and/or connective tissue disease
  • History of hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders.
  • History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism.
  • History of ongoing pregnancy, active breastfeeding, cancer, and epilepsy

About Albert Einstein College Of Medicine

Albert Einstein College of Medicine is a leading academic institution dedicated to advancing biomedical research and medical education. Situated in the Bronx, New York, it is renowned for its commitment to innovative research and training the next generation of physicians and scientists. The college actively engages in a wide range of clinical trials, focusing on translating scientific discoveries into effective therapies and improving patient care. With a collaborative approach that involves multidisciplinary teams, Albert Einstein College of Medicine aims to address significant health challenges and contribute to the global medical community through rigorous research and evidence-based practices.

Locations

Elmsford, New York, United States

Patients applied

0 patients applied

Trial Officials

Kseniya Kobets, MD

Principal Investigator

Montefiore Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials